Integral Health Asset Management
Latest statistics and disclosures from Integral Health Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are VKTX, INSM, THC, BSX, CYTK, and represent 21.13% of Integral Health Asset Management's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$49M), ABBV (+$25M), MRK (+$24M), UHS (+$23M), WBA (+$23M), TARS (+$21M), HUM (+$21M), BRKR (+$21M), ISRG (+$20M), ACLX (+$18M).
- Started 43 new stock positions in CRL, SWAV, RGEN, HUM, ABBV, EXAS, BRKR, KROS, SYRE, MREO.
- Reduced shares in these 10 stocks: ARGX (-$34M), CYTK (-$25M), MDT (-$24M), , AMGN (-$18M), BDX (-$17M), INSP (-$16M), VTYX (-$15M), COR (-$15M), NTRA (-$14M).
- Sold out of its positions in AKRO, AMGN, ARGX, BDX, BBIO, CTLT, Cooper Companies, 89bio, NVST, HCA.
- Integral Health Asset Management was a net buyer of stock by $163M.
- Integral Health Asset Management has $1.1B in assets under management (AUM), dropping by 49.14%.
- Central Index Key (CIK): 0001773206
Tip: Access up to 7 years of quarterly data
Positions held by Integral Health Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Integral Health Asset Management
Integral Health Asset Management holds 77 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Viking Therapeutics Put Option (VKTX) | 5.7 | $62M | -6% | 750k | 82.00 |
|
| Insmed Com Par $.01 (INSM) | 4.5 | $49M | NEW | 1.8M | 27.13 |
|
| Tenet Healthcare Corp Com New (THC) | 4.1 | $45M | -21% | 425k | 105.11 |
|
| Boston Scientific Corporation (BSX) | 3.8 | $41M | +9% | 600k | 68.49 |
|
| Cytokinetics Com New (CYTK) | 2.9 | $32M | -43% | 450k | 70.11 |
|
| Merck & Co (MRK) | 2.9 | $31M | +370% | 235k | 131.95 |
|
| Encompass Health Corp (EHC) | 2.7 | $29M | +40% | 350k | 82.58 |
|
| Walgreen Boots Alliance (WBA) | 2.6 | $28M | +420% | 1.3M | 21.69 |
|
| Anthem (ELV) | 2.4 | $26M | +100% | 50k | 518.54 |
|
| Abbvie (ABBV) | 2.3 | $25M | NEW | 135k | 182.10 |
|
| Universal Hlth Svcs CL B (UHS) | 2.1 | $23M | NEW | 125k | 182.46 |
|
| Novartis Sponsored Adr (NVS) | 2.0 | $22M | +12% | 225k | 96.73 |
|
| Tarsus Pharmaceuticals (TARS) | 2.0 | $21M | NEW | 590k | 36.35 |
|
| Moonlake Immunotherapeutics Class A Ord Call Option (MLTX) | 2.0 | $21M | -16% | 420k | 50.23 |
|
| Longboard Pharmaceuticals In (LBPH) | 2.0 | $21M | +28% | 975k | 21.60 |
|
| Humana (HUM) | 1.9 | $21M | NEW | 60k | 346.72 |
|
| Neurocrine Biosciences (NBIX) | 1.9 | $21M | +76% | 150k | 137.92 |
|
| Bruker Corporation (BRKR) | 1.9 | $21M | NEW | 220k | 93.94 |
|
| Intuitive Surgical Com New (ISRG) | 1.9 | $20M | NEW | 50k | 399.09 |
|
| Blueprint Medicines (BPMC) | 1.8 | $20M | +320% | 210k | 94.86 |
|
| Arcellx Common Stock (ACLX) | 1.6 | $18M | NEW | 255k | 69.55 |
|
| Charles River Laboratories (CRL) | 1.6 | $18M | NEW | 65k | 270.95 |
|
| Regeneron Pharmaceuticals (REGN) | 1.5 | $16M | NEW | 17k | 962.49 |
|
| Regenxbio Inc equity us cm (RGNX) | 1.5 | $16M | NEW | 760k | 21.07 |
|
| Penumbra (PEN) | 1.5 | $16M | NEW | 70k | 223.18 |
|
| Vera Therapeutics Cl A (VERA) | 1.4 | $16M | NEW | 360k | 43.12 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.4 | $15M | +62% | 325k | 46.81 |
|
| Icon SHS (ICLR) | 1.4 | $15M | NEW | 45k | 335.95 |
|
| Crispr Therapeutics Namen Akt (CRSP) | 1.4 | $15M | -20% | 220k | 68.16 |
|
| Cigna Corp (CI) | 1.3 | $15M | -33% | 40k | 363.19 |
|
| Krystal Biotech (KRYS) | 1.3 | $14M | +14% | 80k | 177.93 |
|
| Dex (DXCM) | 1.3 | $14M | -42% | 100k | 138.70 |
|
| Revolution Medicines (RVMD) | 1.3 | $14M | -20% | 420k | 32.23 |
|
| Shockwave Med (SWAV) | 1.2 | $13M | NEW | 40k | 325.63 |
|
| Avantor (AVTR) | 1.2 | $13M | -4% | 500k | 25.57 |
|
| AmerisourceBergen (COR) | 1.1 | $12M | -54% | 50k | 242.99 |
|
| Tenaya Therapeutics (TNYA) | 1.1 | $12M | NEW | 2.3M | 5.23 |
|
| Cooper Cos (COO) | 1.0 | $11M | NEW | 110k | 101.46 |
|
| EXACT Sciences Corporation Call Option (EXAS) | 1.0 | $10M | NEW | 150k | 69.06 |
|
| Sana Biotechnology (SANA) | 0.9 | $9.8M | NEW | 980k | 10.00 |
|
| Inari Medical Ord (NARI) | 0.9 | $9.6M | -42% | 200k | 47.98 |
|
| Eli Lilly & Co. (LLY) | 0.9 | $9.3M | -52% | 12k | 777.96 |
|
| Repligen Corporation (RGEN) | 0.9 | $9.2M | NEW | 50k | 183.92 |
|
| Alpine Immune Sciences (ALPN) | 0.8 | $9.1M | NEW | 230k | 39.64 |
|
| Elanco Animal Health (ELAN) | 0.8 | $9.0M | -26% | 550k | 16.28 |
|
| Apellis Pharmaceuticals (APLS) | 0.8 | $8.8M | NEW | 150k | 58.78 |
|
| Intra Cellular Therapies (ITCI) | 0.8 | $8.7M | -6% | 125k | 69.20 |
|
| Evolent Health Cl A (EVH) | 0.8 | $8.2M | NEW | 250k | 32.79 |
|
| Tandem Diabetes Care Com New (TNDM) | 0.7 | $8.0M | +73% | 225k | 35.41 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.7 | $8.0M | NEW | 250k | 31.86 |
|
| Alnylam Pharmaceuticals (ALNY) | 0.7 | $7.5M | NEW | 50k | 149.45 |
|
| Oscar Health Cl A (OSCR) | 0.7 | $7.4M | NEW | 500k | 14.87 |
|
| Merus N V (MRUS) | 0.7 | $7.4M | NEW | 165k | 45.03 |
|
| Macrogenics (MGNX) | 0.7 | $7.4M | NEW | 500k | 14.72 |
|
| Cabaletta Bio (CABA) | 0.7 | $7.3M | +28% | 425k | 17.06 |
|
| Inspire Med Sys (INSP) | 0.7 | $7.1M | -68% | 33k | 214.79 |
|
| Alkermes SHS (ALKS) | 0.6 | $6.8M | -9% | 250k | 27.07 |
|
| Roivant Sciences SHS (ROIV) | 0.6 | $6.3M | +33% | 600k | 10.54 |
|
| Beigene Sponsored Adr (BGNE) | 0.6 | $6.3M | NEW | 40k | 156.39 |
|
| Relay Therapeutics (RLAY) | 0.6 | $6.0M | -9% | 725k | 8.30 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.5 | $5.8M | NEW | 325k | 17.76 |
|
| PerkinElmer (RVTY) | 0.5 | $5.3M | -50% | 50k | 105.00 |
|
| Align Technology (ALGN) | 0.5 | $4.9M | NEW | 15k | 327.92 |
|
| Natera (NTRA) | 0.4 | $4.6M | -75% | 50k | 91.46 |
|
| Laboratory Corp Amer Hldgs Com New (LH) | 0.4 | $4.4M | NEW | 20k | 218.46 |
|
| Agilent Technologies Inc C ommon (A) | 0.4 | $4.4M | NEW | 30k | 145.51 |
|
| Spyre Therapeutics Com New (SYRE) | 0.4 | $3.8M | NEW | 100k | 37.93 |
|
| Sage Therapeutics (SAGE) | 0.3 | $3.7M | NEW | 200k | 18.74 |
|
| 89bio (ETNB) | 0.3 | $3.5M | NEW | 300k | 11.64 |
|
| Editas Medicine (EDIT) | 0.3 | $3.3M | NEW | 450k | 7.42 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.3 | $3.2M | NEW | 500k | 6.38 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.3 | $3.1M | NEW | 950k | 3.30 |
|
| Guardant Health (GH) | 0.3 | $3.1M | -53% | 150k | 20.63 |
|
| Apogee Therapeutics (APGE) | 0.2 | $2.7M | NEW | 40k | 66.45 |
|
| Keros Therapeutics (KROS) | 0.2 | $2.6M | NEW | 40k | 66.20 |
|
| Axsome Therapeutics (AXSM) | 0.2 | $2.4M | NEW | 30k | 79.80 |
|
| Fate Therapeutics (FATE) | 0.1 | $1.5M | NEW | 200k | 7.34 |
|
Past Filings by Integral Health Asset Management
SEC 13F filings are viewable for Integral Health Asset Management going back to 2019
- Integral Health Asset Management 2024 Q1 filed May 15, 2024
- Integral Health Asset Management 2023 Q3 filed Nov. 14, 2023
- Integral Health Asset Management 2023 Q2 filed Aug. 11, 2023
- Integral Health Asset Management 2023 Q1 filed May 9, 2023
- Integral Health Asset Management 2022 Q4 filed Feb. 13, 2023
- Integral Health Asset Management 2022 Q3 filed Nov. 14, 2022
- Integral Health Asset Management 2022 Q2 filed Aug. 3, 2022
- Integral Health Asset Management 2022 Q1 filed May 12, 2022
- Integral Health Asset Management 2021 Q4 filed Feb. 2, 2022
- Integral Health Asset Management 2021 Q3 filed Nov. 12, 2021
- Integral Health Asset Management 2021 Q2 restated filed Aug. 30, 2021
- Integral Health Asset Management 2021 Q2 filed Aug. 13, 2021
- Integral Health Asset Management 2021 Q1 filed May 10, 2021
- Integral Health Asset Management 2020 Q4 filed Feb. 16, 2021
- Integral Health Asset Management 2020 Q3 filed Nov. 16, 2020
- Integral Health Asset Management 2020 Q2 filed Aug. 14, 2020